Corona Remedies Q1 FY27 Results (NSE: CORONA)
Signal: Margin expansion
The read
Q1FY27 marks a strong inflection: revenue growth accelerated to 21.9% YoY (vs 20.23% in FY26), EBITDA margin expanded 190 bps YoY to 22.0% — the best margin print in six quarters — driven by operating leverage and brand-building efficiencies. PAT growth of 30.1% YoY comfortably outpaced revenue. The company also commissioned its EU-GMP approved female hormone plant on June 30, 2026, which will support future therapy expansion.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹422.43 Cr | 21.9% | 19.7% |
| EBIT | ₹83.04 Cr | N/A | |
| Net profit | ₹60.11 Cr | 30.1% | |
| EPS | ₹9.83 | N/A | |
| EBIT margin | 22.8% |
P&L walk
Revenue grew 21.9% YoY to ₹422.43 Cr, EBITDA margin expanded 190 bps to 22.0% driven by operating leverage and brand building efficiencies; PAT grew 30.1% YoY outpacing revenue growth
Key positives
- Revenue grew 21.9% YoY to ₹422.4 Cr, outpacing the Indian Pharmaceutical Market (IPM) by 1.9x as per MAT June'26
- EBITDA margin expanded 190 bps YoY to 22.0% — EBITDA grew 33.5% YoY vs revenue growth of 21.9%, demonstrating operating leverage
- PAT grew 30.1% YoY to ₹60.1 Cr, with PAT margin improving 90 bps to 14.2%
- Market rank improved to 26th (vs 29th a year ago); maintains 5th rank in Gynaecology therapy
- Commissioned EU-GMP approved female hormone manufacturing facility on June 30, 2026, expanding manufacturing capabilities
Key concerns
- QoQ comparisons show revenue growth of 19.7% but earlier quarters (Q4FY26 rev ₹353 Cr) had softer base; trend needs monitoring
- No disclosure on R&D spend as % of revenue; critical for pharma sustainability and new product pipeline
Research and educational content only. Not investment advice.